AU Patent

AU2021241682B2 — Compositions and methods of treating muscle dystrophy

Assigned to Avidity Biosciences Inc · Expires 2026-02-12 · 0y expired

What this patent protects

Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle dystrophy (DM1).

USPTO Abstract

Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle dystrophy (DM1).

Drugs covered by this patent

vutrisiran-sodium (VUTRISIRAN SODIUM)

Patent Metadata

Patent number: AU2021241682B2
Jurisdiction: AU
Classification: —
Expires: 2026-02-12
Drug substance claim: No
Drug product claim: No
Assignee: Avidity Biosciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.